Evaluation of Mirtazapine and Folic Acid for Schizophrenia:

Schizophrenia Clinical Trial

— RECOVERY2  

Official title:

Multicentre Randomised Double-blind, Placebo-controlled 2x2 Factorial Trial Investigating the Effects of Adding Mirtazapine and Folic Acid to Existing Therapy for Patients With Schizophrenia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01263080
• Other study ID #: RECOVERY2
• Status: Completed
• Phase: Phase 4
• First received: December 17, 2010
• Last updated: August 1, 2016
• Start date: November 2010
• Est. completion date: December 2012

Study information

• Verified date: August 2016
• Source: Capital Medical University
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Multicentre randomised double-blind, placebo-controlled 2x2 factorial trial investigating the effects of adding mirtazapine and folic acid to existing therapy for patients with schizophrenia

Description:

The combination of mirtazapine plus antipsychotic potentially offers considerable benefit for patients with schizophrenia. Folic acid is a promising adjunctive therapy for schizophrenia that may also provide benefits for patients with other mental disorders. Furthermore the effects of folic acid may be affected by genotype.

The trial will investigate the effects of adding mirtazapine and the effects of adding folic acid to treatments for schizophrenia. At randomisation, patients will be separately randomised to mirtazapine or placebo and to folic acid or placebo.

Randomised, double-blind, placebo-controlled 2x2 factorial trial with 12-week follow-up.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 333
• Est. completion date: December 2012
• Est. primary completion date: December 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Inpatients or outpatients age 18 to 70 years;

2. Meet DSM-IV criteria for schizophrenia;

3. Signed an informed consent form by patients or their legally acceptable representatives;

4. PANSS total score >=60 and at least one item of P1, P2, P3, P5 or P6 >=4 to ensure subject has current active psychotic symptoms - i.e. hallucinations, delusions, thought disorder;

5. Subjects who are currently taking effective dose of antipsychotic;

6. Women must agree to practice an effective method of birth control if they are sexually active before entry and throughout the study.

Exclusion Criteria:

1. Meet any other DSM-IV Axis I disorders;

2. Meet DSM-IV criteria for substance abuse or dependence;

3. Have been treatment-resistant to 2 or more kinds of antipsychotics with sufficient dosage for at least 4 weeks, or require clozapine treatment, or have received clozapine treatment within 1 month prior to randomization;

4. Subjects are actively suicidal or judged clinically to be at risk of serious suicidal or violent behavior in the opinion of the investigator;

5. Have serious or unstable medical illness (e.g., cardiovascular disease, neurologic, hematologic, renal, hepatic, immunologic, endocrine, or other systemic illness), or have any clinically significant abnormality on laboratory test or ECG which indicate severe medical conditions;

6. Have received electroconvulsive therapy within 28 days before randomization;

7. Have received long acting antipsychotic within 1 treatment cycle before randomization;

8. Have received antidepressant within 14 days, or have received MAOIs within 4 weeks before randomization or require antidepressive treatment;

9. History of prostatic hypertrophy or dysuria;

10. History of narrow-angle glaucoma or elevation of intraocular pressure;

11. Known or suspected history of allergy or have contradiction to mirtazapine or folic acid;

12. Known have currently requirement of taking mirtazapine or folic acid;

13. Women who are pregnant or nursing;

14. Have previously completed or withdrawn from this study, or participated in a clinical trial of another drug within 30 days.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Schizophrenia

Intervention

Drug:
• mirtazapine
mirtazapine 30mg QD
• folic acid placebo
folic acid placebo 1 tablet QD
• mirtazapine placebo
mirtazapine placebo 1 tablet QD
• folic acid
folic acid 0.4mg QD

Locations

Country	Name	City	State
China	Beijing Anding Hospital, Capital Medical University	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Capital Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To compare the efficacy of mirtazapine and placebo for treatment of symptoms associated with schizophrenia		baseline, week4, week8, week12	No
Secondary	To compare the efficacy of folic acid and placebo for treatment of symptoms of schizophrenia		baseline, week4, week8, week12	No
Secondary	To compare the efficacy of mirtazapine and placebo for treatment of negative symptoms of schizophrenia		baseline, week4, week8, week12	No
Secondary	To compare the efficacy of folic acid and placebo for treatment of negative symptoms of schizophrenia		baseline, week4, week8, week12	No
Secondary	To compare the safety and tolerability of mirtazapine and placebo in patients with schizophrenia		baseline, week4, week8, week12	Yes
Secondary	To compare the safety and tolerability of folic acid and placebo in patients with schizophrenia		baseline, week4, week8, week12	Yes